Growing Public Health Concern
Tuberculosis remains one of the deadliest infectious diseases globally, and Indonesia ranks among the countries with the highest number of cases. Drug-resistant tuberculosis (often called TB RO) complicates this situation because it does not respond to standard first-line medications like isoniazid and rifampicin. This leads to longer treatment periods, higher healthcare costs, and increased mortality rates.
In Papua Province, the number of drug-resistant TB cases has steadily increased in recent years, reflecting broader national and global trends. Health systems face mounting pressure to improve detection, treatment adherence, and prevention strategies. Understanding the drivers of drug resistance is essential for policymakers and healthcare providers.
How the Study Was Conducted
The research analyzed data from 272 tuberculosis patients across Papua Province using a cross-sectional observational design. Instead of following patients over time, the study examined existing medical records at a single point to identify patterns.
Researchers used statistical methods including chi-square tests and binary logistic regression to assess relationships between various risk factors and the incidence of drug-resistant TB. The analysis focused on demographic variables, medical history, and behavioral factors such as medication adherence.
Key Findings at a Glance
The study identified several factors significantly associated with drug-resistant tuberculosis:
- Previous TB treatment history emerged as the strongest predictor
- HIV/AIDS comorbidity significantly increased risk
- Diabetes mellitus (DM) also contributed to higher susceptibility
- Poor medication adherence played a major role in resistance development
- Occupation showed a statistical relationship with TB incidence
Meanwhile, factors such as age, gender, ethnicity, and contact history were not found to have a significant impact.
One of the most striking findings is the magnitude of risk linked to treatment history. Patients who had previously undergone TB treatment were more than 12 times more likely to develop drug-resistant TB compared to those without such history.
Why Treatment History Matters Most
The study underscores a key issue in TB control: incomplete or improper treatment. When patients fail to complete their medication regimen or receive inadequate treatment, tuberculosis bacteria can survive and evolve resistance to drugs.
As the researchers from Cenderawasih University explain, prior treatment exposure creates conditions where “resistant strains of Mycobacterium tuberculosis can survive and multiply,” making future infections much harder to treat.
This finding reinforces the importance of strict treatment supervision, consistent drug supply, and patient education to ensure adherence.
The Role of HIV and Diabetes
The study also highlights the role of comorbid conditions:
- HIV/AIDS weakens the immune system, making individuals more vulnerable to infection and reducing the body’s ability to fight TB bacteria.
- Diabetes mellitus affects immune response and metabolism, creating a favorable environment for bacterial growth and increasing the risk of complications.
Patients with HIV or diabetes require integrated care approaches, as managing these conditions alongside TB is essential to prevent drug resistance.
Medication Adherence: A Critical Factor
Non-adherence to TB medication remains one of the most preventable causes of drug resistance. Patients who skip doses, stop treatment early, or take incorrect dosages allow bacteria to survive and adapt.
The study emphasizes that adherence is not just a medical issue but also a behavioral and social one. Factors such as stigma, lack of knowledge, and limited healthcare access can all reduce compliance.
Real-World Impact and Policy Implications
The findings have direct implications for public health strategies in Indonesia, particularly in Papua:
- Strengthening treatment monitoring systems to ensure patients complete therapy
- Improving HIV and TB integrated care programs
- Enhancing patient education and community awareness
- Expanding screening for high-risk groups, especially those with prior TB treatment
- Improving data recording and reporting systems for TB cases
By focusing on these areas, health authorities can reduce the emergence of drug-resistant TB and improve treatment outcomes.
Expert Insight
The research team from Cenderawasih University emphasizes that addressing drug-resistant TB requires both medical and systemic solutions. In their analysis, they highlight that treatment history is not just a clinical variable but a reflection of healthcare system performance and patient behavior.
They note that ensuring consistent and high-quality TB treatment is the most effective way to prevent resistance from developing in the first place.
Author Profile
Hasriyati, MPH – Public Health researcher, Faculty of Public Health, Cenderawasih University
Hasmi, MPH – Epidemiology expert, Faculty of Public Health, Cenderawasih University
Arius Togodly, MPH – Public health specialist, Cenderawasih University
Sarce Makaba, MPH – Researcher in infectious disease epidemiology
Agus Zainuri, MPH – Health systems and policy analyst
Muhammad Akbar Nurdin, MPH – Public health data analyst
All authors are affiliated with the Master of Public Health Program, Faculty of Public Health, Cenderawasih University of Jayapura, Indonesia.
0 Komentar